Jemincare Group commences phase one JMB2002 clinical trial

Jemincare begins phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002

Vera Therapeutics Launches with USD 80m Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease

Transgene, BioInvent Receive Approval from ANSM to Proceed with Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

Ixaka Launches as an Integrated Cell and Gene Therapy Company

Enhertu Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer

First Patient Dosed in Phase II Trial of Debiopharm's Antiviral Alisporivir Against Covid-19

Metrion Biosciences and LifeArc extend neuroscience-Ion channel drug discovery collaboration for a further 12 months

GenSight Biologics provides update on cash position and operations

European Medicines Agency grants PRIME designation to Tessa Therapeutics' lead autologous CD30 CAR-T therapy

Grifols to start Spanish clinical trial for new COVID-19 drug

Genkyotex SA's Phase 1 study in oral setanaxib demonstrated tolerance at the doses of up to 1600mg/day for treating PBC

Feinstein Institutes to conduct USD4m research perinatal depression led by Dr Kristina Deligiannidis, MD

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

Janssen Receives FDA Approval of Darzalex Faspro as Treatment for Newly Diagnosed Patients with Light Chain Amyloidosis